Quantitative Concept – Page 17

nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines

5 months ago talkbio0Tagged Biotechnology, Chroma Medicine, epigenetic editing, financing characteristics, genetic medicines, Merger, nChroma, Non-Viral Delivery

nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing

2024 Biotech IPOs: Insights and Trends

5 months ago talkbio0Tagged 2024, biopharma sector, biotech, Capital, Health care facility, innovation, Investments, IPO, IPOs, public entity, trends qualifier, venture

Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.

Dimension Secures $500M for Second Fund, Focusing on the Intersection of Science and Technology

5 months ago talkbio0Tagged Aortic Valve Insufficiency, biotech, Capital, Dimensions, innovation, Machine Learning, Science, Technology, venture

Dimension, Venture Capital, Science, Technology, Biotech, AI, Machine Learning, Life Sciences, Innovation

Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

5 months ago talkbio0Tagged Clinical Trials, Keytruda, Lynparza, ovarian neoplasm, Progression-Free Survival, Survival

Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival

Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law

5 months ago talkbio0Tagged 1103, Arkansas, Contract agreement, court, drug price, federal, Pharmacy facility, PhRMA, Programs - Publication Format, Supreme

340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption

Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility

5 months ago talkbio0Tagged Biological Factors, biomanufacturing, bony process, Characterization, Continuous, Efficiency, Manufacturing, Modular Facilities, Pliability, Precision medicines, Regulatory Compliance, Strategic Roadmap, technology roadmap

Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing

Diverse Partnerships with Drexel University: Enhancing Educational Opportunities

5 months ago talkbio0Tagged career, Drexel, educational collaborations, Financial savings, professional development, tuition, University partnerships

Drexel University partnerships, educational collaborations, tuition savings, career advancement, professional development

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

5 months ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

5 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy

Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs

5 months ago talkbio0Tagged Agenus, Antineoplastic Agents, BOT/BAL, botensilimab/balstilimab, Financial cost, layoffs, strategic realignment

Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development